Navigation Links
Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published

er of resistant clones.

According to Professor Lundgren, "It is widely known that melanoma cells often develop resistance to recombinant alpha interferon therapies. We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R) clearly suppressing resistance development far more efficiently than Intron(R) A after four weeks of treatment. One possibility is that multiple subtypes of alpha interferon in Multiferon(R) are working synergistically to eradicate resistant cell clones. If Multiferon(R) is indeed suppressing the development of resistant melanoma clones, this effect may have played a role in improving overall survival in melanoma patients in Viragen's previously reported Phase II/III melanoma trial, published last year in Acta Oncologica."

In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is preparing to proceed with a European Union (EU) regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.

* Intron(R) A is registered trademark of Schering-Plough Corporation

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. The American Cancer Society estimates that in 2006 there were 62,190 new cases of melanoma in the United States and about 7,910 people died of this disease.

About Multiferon(R):

Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.

Multiferon(R) differs from single-subtype recombinant alpha in
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... Inc.,(Amex: CUR ) today announced that it ... Clinic pertaining to Targeted Spinal Cord,Therapeutics Delivery. All ... formerly of Cleveland Clinic, now at Emory University., ... are very pleased to have licensed-in these important ...
... today,announced the Company,s lead product, amadacycline, formerly PTK 0796, ... Breaker,poster presentation at the 48th Interscience Conference on Antimicrobial,Agents ... D.C.,from October 25 - October 28, 2008., More ... Sunday, October 26, 12:15 - 1:15 pm EST ...
Cached Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2
(Date:8/22/2014)... Mi40x , the latest guide from expert ... how they can use a simple 4-minute trick to pack ... weeks has caught the attention of Shane Michaels, prompting an ... most well-known bodybuilders in the industry, and if he uses ... in itself is a testament to how effective this program ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
(Date:8/22/2014)... Orange, NJ. August 22, 2014. A new ... that persons with multiple sclerosis (MS) may be ... rehabilitation. The study was epublished ahead of print ... Goverover, Helen Genova, Hali Griswold, Nancy D. Chiaravalloti ... in persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... than half of Americans know two particular fats boost ... Fewer than half of Americans realize there are two ... a new survey shows. , So, while many have ... fats and saturated fats, the American Heart Association (AHA) ...
... specific pieces of non-coding genetic material known as microRNAs ... cancer to other parts of the body. Researchers at ... Ohio State University Medical Center in Columbus have identified ... The findings, reported at the annual meeting of the ...
... ... Center, ... planning and interiors,firm, has transformed a shuttered South of Market warehouse ... As the new "front door" for the downtown university, the,former Swallow ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
... CHAPEL HILL, N.C., May 30 Creating an ... of a new product,s introduction.,A product,s promotion relies ... it.,Top benchmark companies ensure that they create effective, ... of a new product., The detailed report ...
... 30 Members of District,1199C of the National ... morning (Friday) ratified a four-year contract agreement with,Hahnemann ... increase in,wages and benefits., District 1199C represents ... reached with the hospital following some 16 and ...
Cached Medicine News:Health News:Some Fats Deserve Change of Heart 2Health News:Jefferson, Ohio State team find gene signature profile for metastasis 2Health News:Golden Gate University Opens New Student Services Center 2Health News:MDwise Enrollment Exceeds 300,000 Members 2Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2
... and helix provide distal shaft column ... Construction eliminates springback and provides for ... to provide a better fit for ... ,Trimmable ends provide a custom ...
... The AMS 650™ and 600M™ malleable penile ... patientsespecially those with limited dexterity. These implants ... the patient to position them in an ... the penis rigid enough for sexual intercourse ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: